期刊
ARTHRITIS RESEARCH & THERAPY
卷 12, 期 3, 页码 -出版社
BMC
DOI: 10.1186/ar3047
关键词
-
类别
资金
- Swedish Medical Society
- Research and Education fund of Gothenburg (FOU/LUA)
- Medical Society of Gothenburg
- Swedish Association against Rheumatism
- Gothenburg Association against Rheumatism
- King Gustaf V:s 80-year Foundation
- Swedish Medical Research Council
- Nanna Svartz' Foundation
- Rune och Ulla Almlovs foundation
- Family Tholens and Kristlers Foundation
- National Inflammation Network
- Foundation for Strategic Research
- ROCHE AB Sweden
- University of Gothenburg
Introduction: Rheumatoid arthritis (RA) is frequently complicated with infections. The aim of our study was to evaluate vaccination response in patients with RA after B-cell depletion by using rituximab. Methods: Influenza (Afluria) and pneumococcal polysaccharides (Pneumo23) vaccines were given 6 months after rituximab (post-RTX group, n = 11) or 6 days before rituximab treatment (pre-RTX group; n = 8). RA patients never exposed to RTX composed the control group (n = 10). Vaccine-specific cellular responses were evaluated on day 6 after vaccination, and vaccine-specific humoral responses, on day 21. Results: On day 6 after vaccination, formation of influenza-specific B cells was lower in post-RTX group as compared with the pre-RTX group and controls (P = 0.04). Polysaccharide-specific B cells were found in 27% to 50%, being equally distributed between the groups. On day 21, the impairment of humoral responses was more pronounced with respect to influenza as compared with the pneumococcal vaccine and affected both IgG and light-chain production. Total absence of influenza-specific IgG production was observed in 55% of the post-RTX group. Conclusions: RTX compromises cellular and humoral vaccine responses in RA patients. However, repeated RTX treatment or previous anti-tumor necrosis factor (anti-TNF) treatment did not accentuate these defects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据